ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Sam_123
|
226 |
83K |
1 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
83K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Sam_123
|
226 |
83K |
5 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
83K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
Sam_123
|
78 |
25K |
2 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
25K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
Sam_123
|
78 |
25K |
12 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
25K
|
12
|
|
ASX - By Stock
|
OZM |
Re:
Ann: Top 20 Holders
|
|
Sam_123
|
18 |
5.5K |
0 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
18
|
5.5K
|
0
|
|
ASX - By Stock
|
OZM |
Re:
Ann: Top 20 Holders
|
|
Sam_123
|
18 |
5.5K |
0 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
18
|
5.5K
|
0
|
|
ASX - By Stock
|
OZM |
Re:
Ann: Top 20 Holders
|
|
Sam_123
|
18 |
5.5K |
0 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
18
|
5.5K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Sam_123
|
1.0K |
518K |
0 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
1.0K
|
518K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Sam_123
|
1.0K |
518K |
20 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
1.0K
|
518K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Sam_123
|
1.0K |
518K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
518K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Sam_123
|
1.0K |
518K |
10 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
518K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Sam_123
|
1.0K |
518K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
518K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
0 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Sam_123
|
796 |
396K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
796
|
396K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
10 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
5 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
26 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
Sam_123
|
1.0K |
419K |
6 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
1.0K
|
419K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Guess the reason for MSB Trading Halt
|
|
Sam_123
|
317 |
157K |
3 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
317
|
157K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
2 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Sam_123
|
796 |
396K |
3 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
796
|
396K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Sam_123
|
796 |
396K |
44 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
396K
|
44
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Sam_123
|
192 |
86K |
2 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
192
|
86K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Did Mesoblast ever received any kind of FDA approval?
|
|
Sam_123
|
14 |
5.5K |
8 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
14
|
5.5K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
Sam_123
|
1.0K |
419K |
7 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
1.0K
|
419K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
5 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Phase 3 DREAM HF-1 read-out
|
|
Sam_123
|
344 |
180K |
15 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
344
|
180K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
1 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
4 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
3 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Sam_123
|
572 |
252K |
10 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
572
|
252K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
1 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
Sam_123
|
139 |
72K |
35 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
139
|
72K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
Sam_123
|
139 |
72K |
14 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
139
|
72K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
Sam_123
|
139 |
72K |
36 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
139
|
72K
|
36
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Sam_123
|
572 |
252K |
13 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
572
|
252K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
Sam_123
|
139 |
72K |
49 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
139
|
72K
|
49
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
Sam_123
|
139 |
72K |
109 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
139
|
72K
|
109
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
Sam_123
|
416 |
132K |
4 |
03/12/20 |
03/12/20 |
ASX - By Stock
|
416
|
132K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
Sam_123
|
416 |
132K |
1 |
03/12/20 |
03/12/20 |
ASX - By Stock
|
416
|
132K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
0 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Sam_123
|
572 |
252K |
25 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
252K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Sam_123
|
811 |
336K |
23 |
30/11/20 |
30/11/20 |
ASX - By Stock
|
811
|
336K
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Sam_123
|
17K |
6.8M |
7 |
30/11/20 |
30/11/20 |
ASX - By Stock
|
17K
|
6.8M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Sam_123
|
17K |
6.8M |
5 |
30/11/20 |
30/11/20 |
ASX - By Stock
|
17K
|
6.8M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Sam_123
|
17K |
6.8M |
17 |
30/11/20 |
30/11/20 |
ASX - By Stock
|
17K
|
6.8M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: CEO Presentation to 2020 Annual General Meeting
|
|
Sam_123
|
13 |
7.5K |
35 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
13
|
7.5K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Sam_123
|
17K |
6.8M |
12 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
17K
|
6.8M
|
12
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Sam_123
|
13K |
5.0M |
12 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
13K
|
5.0M
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Sam_123
|
811 |
336K |
53 |
22/11/20 |
22/11/20 |
ASX - By Stock
|
811
|
336K
|
53
|
|